Breast cancer

77 trials 44 recruiting MedDRA PT
77 Registered trials
44 Recruiting
54 Unique sponsors
86 Unique IMPs
46 Commercial trials
Drug classes (ATC)
— ATC code not specified 45
L Oncology (ATC L) 25
N Neurology/Psychiatry (ATC N) 4
B Haematology (ATC B) 1
A Gastroenterology (ATC A) 2
J Anti-infectives (ATC J) 1
G Urology/Gynaecology (ATC G) 2
H Endocrinology (ATC H) 2
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 39 substances
Antibody-drug conjugate (ADC) 5 substances
CDK inhibitor 4 substances
PARP inhibitor 3 substances
Kinase inhibitor 3 substances
Taxane 3 substances
Monoclonal antibody (tumor, humanized) 3 substances
Monoclonal antibody 2 substances
Colony-stimulating factor 2 substances
SERD 2 substances
Alkylating agent 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Gonadotropin / pituitary hormone 2 substances
Antimetabolite 2 substances
Platinum compound 2 substances
Corticosteroid 2 substances
Checkpoint inhibitor (PD-L1) 1 substance
BTK inhibitor 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Macrolide / aminoglycoside 1 substance
Tetracycline 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Anthracycline 1 substance
Analgesic / antipyretic 1 substance
Phase III: 20 Phase II: 21 Phase I/II: 9 Phase IV: 7 Phase I: 12 Phase I (Other): 1 Phase I (First in Human): 7

Filter these 77 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 77 trials

Phase III

20 trials
  • Amgen Inc. Commercial
    ROMIPLOSTIM
    2023-507149-27-00 5 countries 2019 n=46
    Recruiting
  • AstraZeneca AB Commercial
    OLAPARIB
    2024-512982-15-00 12 countries 2021 n=94
    Recruiting
  • BioNTech SE Commercial
    BNT327; PACLITAXEL ALBUMIN-BOUND
    2025-521884-12-00 8 countries 2026 n=144
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    INAVOLISIB; TRASTUZUMAB, PERTUZUMAB
    2022-502046-28-00 7 countries 2023 n=67
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ALPELISIB; ALPELISIB, ALPELISIB; INAVOLISIB
    2022-502322-41-00 6 countries 2023 n=150
    Ended
  • F. Hoffmann-La Roche AG Commercial
    PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TRASTUZUMAB, PERTUZUMAB
    2023-506380-33-00 3 countries 2022 n=32
    Ended
  • Greenwich LifeSciences Inc. Commercial
    L-ISOLEUCYL-L-ISOLEUCYL-L-SERYL-L-ALANYL-L-VALYL-L-VALYL-GLYCYL-L-ISOLEUCYL-L-LEUCINE; SARGRAMOSTIM
    2023-504323-25-01 10 countries 2024 n=435
    Recruiting
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2023-508960-31-00 8 countries 2024 n=264
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2023-509242-35-00 3 countries 2020 n=1,624
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    RIBOCICLIB
    2024-515769-32-00 1 country 2019 n=1,684
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    ELACESTRANT; RIBOCICLIB
    2025-522484-15-00 3 countries 2026 n=1,520
    Recruiting
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended
  • Istituto Europeo Di Oncologia S.r.l. Academic
    PRASTERONE
    2023-506211-18-00 1 country 2025 n=95
    Recruiting
  • Reinier de Graaf Groep Academic
    IMP not specified
    2023-507847-13-00 1 country 2024 n=67
    Recruiting
  • Unicancer Academic
    ABEMACICLIB
    2024-513005-31-00 1 country 2020 n=180
    Ended
  • Universitaetsklinikum Ulm AöR Academic
    TRASTUZUMAB DERUXTECAN
    2024-516173-76-01 1 country 2025 n=180
    Recruiting
  • University Of Florence Academic
    IMP not specified
    2023-508094-88-00 1 country 2021 n=926
    Recruiting
  • Uniwersytet Jagiellonski Collegium Medicum Academic
    IMP not specified
    2023-507644-37-00 1 country 2024 n=900
    Recruiting
  • Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group Academic
    DENOSUMAB
    2024-513734-38-00 3 countries 2019 n=1,150
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Academic
    CAPIVASERTIB
    2024-511392-15-00 3 countries 2025 n=250
    Recruiting

Phase II

21 trials
  • AstraZeneca AB Commercial
    DURVALUMAB; OLAPARIB
    2023-503529-20-00 5 countries 2022 n=40
    Ended
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2024-517868-33-00 4 countries 2025 n=30
    Ended
  • Blue Earth Diagnostics Ireland Limited Commercial
    GA68-ONCOFAP
    2025-521983-36-00 2 countries n=65
    Pending
  • F. Hoffmann-La Roche AG Commercial
    INAVOLISIB; LETROZOLE; RIBOCICLIB
    2024-518811-20-00 2 countries 2025 n=34
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE
    2023-506618-29-00 6 countries 2021 n=10 Orphan
    Recruiting
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2025-523204-68-00 3 countries 2026 n=100
    Recruiting
  • Pfizer Inc. Commercial
    [(1R,3S)-3-[3-[[5-(METHOXYMETHYL)-2-METHYLPYRAZOLE-3-CARBONYL]AMINO]-1H-PYRAZOL-5-YL]CYCLOPENTYL]N-PROPAN-2-YLCARBAMATE MONOHYDRATE; PF-07220060 MONOHYDRATE
    2023-509504-15-00 3 countries 2023 n=49
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2024-514458-61-01 1 country 2024 n=705
    Ended
  • Azienda Ospedaliero Universitaria Pisana Academic
    AZITHROMYCIN DIHYDRATE; DOXYCYCLINE HYCLATE; SODIUM ASCORBATE
    2024-517993-94-00 1 country n=90
    Pending
  • Centro Di Riferimento Oncologico Di Aviano Academic
    IMP not specified
    2024-513163-57-00 1 country 2024 n=10
    Recruiting
  • Fondazione Oncotech Impresa Sociale Academic
    GIREDESTRANT
    2023-510153-42-00 1 country 2024 n=51
    Ended
  • Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic
    IMIPRAMINE HYDROCHLORIDE
    2023-504943-15-00 1 country 2022 n=180
    Recruiting
  • GBG Forschungs GmbH Academic
    INAVOLISIB; TRASTUZUMAB, PERTUZUMAB
    2022-501152-28-00 7 countries 2022 n=195
    Recruiting
  • Helse Bergen HF Academic
    CYCLOPHOSPHAMIDE
    2024-515135-29-00 1 country 2024 n=63
    Ended
  • Institut De Cancerologie De L Ouest Academic
    CETRORELIX; CHORIOGONADOTROPIN ALFA; FOLLITROPIN BETA; TAMOXIFEN CITRATE
    2024-516282-37-00 1 country 2025 n=100
    Recruiting
  • Institut Regional Du Cancer De Montpellier Academic
    IMP not specified
    2024-515342-16-00 1 country 2024 n=105
    Recruiting
  • Karolinska University Hospital Academic
    GALLIUM (68GA) TEZATABEP MATRAXETAN
    2022-500448-39-00 1 country 2022 n=72
    Ended
  • Oslo University Hospital HF Academic
    BEVACIZUMAB; CAPIVASERTIB
    2023-510093-13-00 1 country 2022 n=150
    Recruiting
  • Unicancer Academic
    PEMBROLIZUMAB
    2023-504620-26-00 2 countries 2024 n=364
    Recruiting

Phase I/II

9 trials
  • Amgen Inc. Commercial
    BEMARITUZUMAB
    2023-505455-44-00 15 countries 2022 n=300
    Ended
  • BioNTech SE Commercial
    BNT327; DB-1303
    2024-517979-20-00 3 countries 2026 n=95
    Recruiting
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-516540-25-00 1 country 2013 n=83
    Ended
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Cyclacel Limited Commercial
    CYC140 MONOHYDROCHLORIDE MONOHYDRATE
    2024-516290-67-00 1 country 2022 n=56
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Genentech Inc. Commercial
    GIREDESTRANT; RGT-419B
    2025-521128-31-00 4 countries 2025 n=73
    Recruiting
  • Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela Academic
    IMP not specified
    2024-512152-38-00 1 country n=100
    Pending
  • Medica Scientia Innovation Research S.L. Academic
    CAPECITABINE; DEXAMETHASONE SODIUM PHOSPHATE; DIPHENHYDRAMINE HYDROCHLORIDE; ERIBULIN MESYLATE; HYDROCORTISONE SODIUM SUCCINATE; LOPERAMIDE HYDROCHLORIDE; PARACETAMOL; TUCATINIB
    2025-524613-89-00 1 country n=129
    Pending

Phase IV

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended
  • GE Healthcare Limited Commercial
    IMP not specified
    2024-517400-11-00 1 country 2024 n=165
    Ended
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-514891-41-00 5 countries 2022 n=7
    Ended
  • Grupo Espanol De Investigacion En Cancer De Ovario Academic
    CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN HYDROCHLORIDE; EXEMESTANE; FULVESTRANT; GEMCITABINE; GOSERELIN ACETATE; NINTEDANIB; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; TRASTUZUMAB
    2022-502706-33-00 1 country 2018 n=8,000
    Recruiting
  • Institut fuer Frauengesundheit GmbH Academic
    RIBOCICLIB
    2024-520290-12-00 1 country 2025 n=548
    Recruiting
  • Rita Fior Academic
    IMP not specified
    2023-509598-22-01 1 country 2025 n=276
    Recruiting
  • Zealand University Hospital Academic
    ROPIVACAINE HYDROCHLORIDE
    2022-501312-34-00 1 country n=30
    Not authorised

Phase I

12 trials
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-511744-27-00 2 countries 2022 n=240
    Ended
  • Duke Street Bio Limited Commercial
    IMP not specified
    2023-508805-26-00 4 countries 2024 n=101
    Recruiting
  • Genentech Inc. Commercial
    IMP not specified
    2023-504491-15-00 6 countries 2020 n=187
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2023-508124-36-00 1 country 2024 n=41
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-516870-31-00 1 country 2025 n=21
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-517746-34-00 1 country n=36
    Pending
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting
  • Rigshospitalet Academic
    IMP not specified
    2024-516786-37-00 1 country 2025 n=140
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2022-501725-21-00 1 country 2024 n=48
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2025-521497-34-00 1 country 2025 n=20
    Recruiting
  • Universitaetsklinikum Wuerzburg AöR Academic
    IMP not specified
    2024-512019-36-00 1 country 2025 n=44
    Recruiting

Phase I (Other)

1 trial
  • AstraZeneca AB Commercial
    IMP not specified
    2024-512161-14-00 5 countries 2025 n=98
    Recruiting

Phase I (First in Human)

7 trials
  • 858 Therapeutics Inc. Commercial
    ETX-19477
    2024-518326-32-00 3 countries n=28
    Pending
  • AstraZeneca AB Commercial
    [11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
    2023-504984-17-00 2 countries 2022 n=176
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Pmv Pharmaceuticals Inc. Commercial
    PC14586
    2023-504251-27-00 4 countries 2024 n=105
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    ABEMACICLIB; AMCENESTRANT; PALBOCICLIB
    2024-512997-89-00 2 countries 2019 n=3
    Ended
  • Ona Therapeutics S.L. Academic
    ONA-255
    2025-522233-62-00 1 country 2025 n=117
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
WSG Westdeutsche Studiengruppe GmbH Commercial 5 Phase II, Phase III 2
AstraZeneca AB Commercial 4 Phase I (Other), Phase II, Phase III, Phase I (First in Human) 3
F. Hoffmann-La Roche AG Commercial 4 Phase II, Phase III 1
Amgen Inc. Commercial 3 Phase I, Phase III, Phase I/II 1
Genentech Inc. Commercial 3 Phase I, Phase I/II 1
Jazz Pharmaceuticals Ireland Limited Commercial 3 Phase II, Phase III 3
Novartis Pharma AG Commercial 2 Phase I, Phase IV 0
BioNTech SE Commercial 2 Phase III, Phase I/II 2
Daiichi Sankyo Inc. Commercial 2 Phase I (First in Human), Phase I/II 2
Cyclacel Limited Commercial 2 Phase I/II 0
Universitaet Muenster Academic 2 Phase I 2
GBG Forschungs GmbH Academic 2 Phase II, Phase III 1
Unicancer Academic 2 Phase II, Phase III 1
Cullinan Therapeutics Inc. Commercial 1 Phase I 0
Duke Street Bio Limited Commercial 1 Phase I 1
Merck Sharp & Dohme LLC Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 1
Bayer Consumer Care AG Commercial 1 Phase II 1
Bicycletx Limited Commercial 1 Phase II 0
Blue Earth Diagnostics Ireland Limited Commercial 1 Phase II 0
New trials by year
2019
4
2020
5
2021
3
2022
12
2023
4
2024
15
2025
19
2026
5
← All indication landscapes